Oh boy, Donald Trump’s approval ratings have hit rock bottom faster than a bad hair day in a wind tunnel, so naturally, he’s pulling out the big guns—or in this case, the big discounts on miracle weight-loss drugs. Picture this: the man who once tweeted about covfefe is now brokering a deal with pharma behemoths Eli Lilly and Novo Nordisk to slash prices on GLP-1s like Wegovy and Zepbound for Medicare and Medicaid folks. It’s government intervention at its finest—Trump strutting into the Oval Office like a reality TV host announcing a prize, declaring it a “triumph” that saves lives and wallets. But hold the confetti: only 10% of beneficiaries qualify (sorry, salad-dodgers without pre-existing conditions), and there’s that awkward moment when a Novo exec face-planted mid-speech. Plus, Trump’s launching “TrumpRx.gov” next year to peddle these bad boys for $350 a month—because nothing says “affordable healthcare” like a website with more walls than his foreign policy. Cynics say it’s all timed for midterms, but hey, if it means cheaper shots at shedding pounds before Thanksgiving, we’ll take the orange-tinted olive branch. Just don’t ask about the fine print; it’s longer than one of his rallies.
Trump Strikes Deal to Offer Americans GLP-1 Drugs for Much Cheaper
